Overweight/obese status associates with favorable outcome in patients with metastatic nasopharyngeal carcinoma: a 10-year retrospective study

Table 3 Univariate and multivariate analyses of covariates associated with progression-free survival in patients with metastatic NPC

Variable	Univariate		Multivariate
Variable	HR (95 % CI)	P	HR (95 % CI)	P
Age (<45 years vs. ≥45 years)	1.01 (0.87–1.18)	0.863	1.03 (0.88–1.20)	0.760
Sex (men vs. women)	1.04 (0.85–1.27)	0.730	1.04 (0.84–1.27)	0.745
UICC T category (T1–2 vs. T3–4)	0.92 (0.79–1.07)	0.289	0.92 (0.78–1.07)	0.274
UICC N category (N0–1 vs. N2–3)	1.23 (1.05–1.43)	0.009	1.29 (1.10–1.51)	0.002
Metastasis onset (synchronous vs. metachronous)	1.04 (0.88–1.23)	0.647	1.17 (0.98–1.39)	0.091
Solitary lesion (no vs. yes)	0.69 (0.55–0.87)	0.001	0.87 (0.68–1.12)	0.281
Lung metastasis (absent vs. present)	0.87 (0.75–1.02)	0.083	0.98 (0.76–1.27)	0.900
Liver metastasis (absent vs. present)	1.50 (1.27–1.77)	<0.001	1.50 (1.19–1.90)	0.001
Bone metastasis (absent vs. present)	1.27 (1.09–1.48)	0.003	1.33 (1.05–1.68)	0.019
Number of involved sites (one vs. two or more)	1.47 (1.25–1.72)	<0.001	1.08 (0.84–1.38)	0.556
Treatment modality (CT vs. CT + LT)	0.68 (0.57–0.81)	<0.001	0.70 (0.58–0.85)	0.001
BMI		0.139^a		0.407^a
Underweight vs. normal weight	0.87 (0.72–1.06)	0.141	0.91 (0.75–1.11)	0.367
Underweight vs. overweight/obese	0.80 (0.64–1.00)	0.042	0.86 (0.68–1.08)	0.181

UICC Union of International Cancer Control; CT chemotherapy; LT local therapy; BMI body mass index; HR hazard ratio; CI confidence interval
^a P value with respect to the significance of differential prognosis between BMI subgroups

ISSN: 2523-3548